A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN ADULT AND ADOLESCENT PARTICIPANTS 12 YEARS OF AGE AND OLDER WITH MODERATE ALOPECIA AREATA

未提供0 个研究点目标入组 336 人开始时间: 待定

适应症

试验速览

暂无简介。

•18 years or older (or the minimum age of consent in accordance with local regulations) at screening. Adolescents (12 to <18 years of age at screening) are also eligible for this study, but only if permitted by the local IRB/EC and local regulatory health authority (if applicable). Where these approvals have not been granted, only participants 18 years of age and older at screening will be enrolled.
•Have a clinical diagnosis of AA with no other etiology of hair loss.
•Have >20% to <50% hair loss of the scalp, as measured by SALT.
•Current AA episode of hair loss >=6 months and <=10 years (Current episode is defined as the continuous period of AA-related scalp hair loss since the last time the subject had no visible scalp patches).

•Diseases or conditions affecting hair loss, including:
•Other types of alopecia (including, but not limited to, traction and scarring alopecia, telogen effluvium). Participants with androgenetic alopecia will be excluded.
•Other scalp disease that may impact AA assessment (eg, scalp psoriasis, dermatitis, etc.).
•Active systemic diseases that may cause hair loss (eg, lupus erythematosus, thyroiditis, systemic sclerosis, lichen planus, etc).

发起方

未提供